Download New Therapeutic Targets in Rheumatoid Arthritis (Progress in Inflammation Research) 2009th Edition PDF

Download New Therapeutic Targets in Rheumatoid Arthritis (Progress in Inflammation Research) 2009th Edition PDF
by Paul-Peter Tak (Editor)

This volume focuses on therapeutic targets that were identified after TNF blockade. All these targets have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter explores the biological rationale of a distinct therapeutic target in great detail. Readers will discover the latest in vitro work, animal models, and results from clinical trials.

During the past decades important breakthroughs have been made in the treatment of rheumatoid arthritis (RA). First, the implementation of low-dose methotrexate and other conventional disease-modifying anti-rheumatic drugs was introduced as an effective treatment. Second, it was recognized that early immunomodulatory treatment is crucial for controlling the disease and its long-term destructive effects more effectively. Parallel advances in research on the pathogenesis of RA and cytokine biology converged in identifying tumor necrosis factor (TNF) as a key factor in inflammation and matrix destruction. The concept arose that elevated TNF concentrations at the sites of inflammation were driving disease pathology, and the removal of excess TNF from sites of inflammation became a therapeutic goal. Clearly, TNF blockade has revolutionized the treatment of RA, as well as other immune-mediated inflammatory diseases. Anti-TNF treatment results in clinical benefit in a significant proportion of the patients, and it has provided proof of concept for the principle of targeted therapy.

Download New Therapeutic Targets in Rheumatoid Arthritis (Progress in Inflammation Research) 2009th Edition PDF

List Price: $289.00 USD
New From: $289.00 USD
Download Ebook pdf Get it $10 USD

 

 

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *